Multiple sclerosis is caused by the immune system attacking the body’s own central nervous system, breaking down the myelin that sheathes and protects CNS nerves, impairing the body’s ability to move normally, and eventually causing paralysis. The T lymphocytes of the mice with which the research team worked are sensitized to brain antigens so that they produce an over-abundance of cytokines, pro-inflammatory chemicals that inflame the CNS, causing demylination of nerve sheaths through the same mechanism and in the same manner as happens in human multiple sclerosis. As in humans with MS, this mouse condition (called experimental autoimmune encephalomyelitis or EAE) can occur in either an acute or relapsing form. The researchers found that oral treatment with lipitor could prevent both the acute and relapsing form of the multiple sclerosis-like disease in the mice, and could also reverse symptoms in mice with the ongoing chronic relapsing form of the disease. Compared with control mice, the mice treated with lipitor had much less CNS inflammation. A close comparison of the lymphocytes of lipitor-treated and control-treated mice showed that lipitor prevented the induction of the pro-inflammatory cytokines and induced secretion of anti-inflammatory cytokines.
Dr. Youssef says that the mechanism by which lipitor affected the immune system suggests that it and other statin medications may have implications for the treatment of multiple sclerosis and other inflammatory autoimmune diseases including insulin-dependent diabetes mellitus and rheumatoid arthritis.
Dr. Youssef and Dr. Steinman are working closely on this study with Dr. Scott Zamvil, University of California at San Francisco. Other members of the research team for this paper are Dr. Pedro Ruiz, Stanford, and Dr. Olaf Stuve, UCLA.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.